Position Title
Postdoctoral Fellow
Dr Cassandra (Cassie) Hatzipantelis is a postdoctoral research fellow with a keen interest in understanding, developing, and advancing novel therapeutic agents for the treatment of neuropsychiatric disorders. They have a PhD in Drug Discovery Biology from Monash University, Australia where she studied the efficacy and molecular mechanisms of a novel class therapeutics to treat schizophrenia. Her work during her PhD was critical to the establishment of the Neuromedicines Discovery Centre spin-out biotech company, Phrenix Therapeutics, wherein the pipelines and frameworks Cassie spearheaded the development of are currently in use to design and test novel, safe and effective antipsychotic and procognitive agents. Now in the Olson Lab and as a research fellow for the IPN, Cassie works on various projects related to the pharmacology of psychedelic drugs and their role in neurophysiology, neuropsychiatric pathophysiology, and in the treatment of neuropsychiatric disorders.
- Monash University's Institute of Pharmaceutical Sciences - Ph.D., Drug Discovery Biology (2022)
- Monash University - Bachelor of Pharmaceutical Sciences (advanced)
- First Class Honours (Australian equivalent to Summa Cum Laude)
- Neuropsychopharmacology
- CNS Drug Discovery
- GPCR Molecular Pharmacology
- Orphan GPCRs
- Hatzipantelis CJ, Liu M, Love A, Leventhal SJ, Maera H, Viswanathan S, Avetisyan E, Belinsky L, Rangel MM, Jain NJ, Kelly M, Copeland C, Khatib YA, Fiehn O, Olson DE, Stolzenberg DS. Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring. Nat Commun. 2025
- Hatzipantelis CJ, Cameron LP, Liu M, Patel SD, Saeger HN, Vernier AMM, Khatib YA, Willis BJ, Lanoue L, Fiehn O, Olson DE. Indolethylamine N-Methyltransferase Deletion Impacts Mouse Behavior without Disrupting Endogenous Psychedelic Tryptamine Production. ACS Chem Neurosci. 2025
- Tuck JR, Dunlap LE, Khatib YA, Hatzipantelis CJ, Weiser Novak S, Rahn RM, Davis AR, Mosswood A, Vernier AMM, Fenton EM, Aarrestad IK, Tombari RJ, Carter SJ, Deane Z, Wang Y, Sheridan A, Gonzalez MA, Avanes AA, Powell NA,…Olson DE. Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proc Natl Acad Sci U S A. 2025
- Hatzipantelis CJ, Olson DE. The Effects of Psychedelics on Neuronal Physiology. Annu Rev Physiol. 2024
- Hatzipantelis CJ. Enhancement of Haloperidol-Induced Catalepsy by GPR143, an l-DOPA Receptor, in Striatal Cholinergic Interneurons. J Neurosci. 2024
- Lu Y, Hatzipantelis CJ, Langmead CJ, Stewart GD. Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia. Br J Pharmacol. 2024
- Spark DL, Vermeulen MH, de la Fuente Gonzalez RA, Hatzipantelis CJ, Rueda P, Sepehrizadeh T, De Veer M, Mannoury la Cour C, Fornito A, Langiu M, Stewart GD, Nithianantharajah J, Langmead CJ. Gpr88 Deletion Impacts Motivational Control Without Overt Disruptions to Striatal Dopamine. Biol Psychiatry Glob Open Sci. 2022
- Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ. Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia. ACS Pharmacol Transl Sci. 2020
- Hatzipantelis CJ, Lu Y, Spark DL, Langmead CJ, Stewart GD. β-Arrestin-2-Dependent Mechanism of GPR52 Signaling in Frontal Cortical Neurons. (2020). ACS Chem. Neurosci.
- Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
- Students of Brain Research Network
- Biological Psychiatry Australia (BPA)